Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
Doxorubicin (DOX) is a cytostatic drug with a broad spectrum of anticancer activity that has been used in oncology for over 50 years. Among many adverse effects in humans, the most dangerous is late dilated cardiomyopathy, which appears even years after completion of therapy. However, in cats, the c...
Saved in:
Main Authors: | Szponar Jaroslaw, Gorska Agnieszka, Ostrowska-Lesko Marta, Wielgomas Bartosz, Mandziuk Slawomir |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2024-12-01
|
Series: | Current Issues in Pharmacy and Medical Sciences |
Subjects: | |
Online Access: | https://doi.org/10.2478/cipms-2024-0038 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01) -
Cardio- and nephroprotective effects of fractions isolated from Lycium barbarum (goji berry) in models of cardio- and nephrotoxicity in rats
by: Nadezhda Hvarchanova, et al.
Published: (2023-03-01) -
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane
by: Marijke Linschoten, et al.
Published: (2025-01-01) -
The risk of peripartum cardiomyopathy among pediatric, adolescent, and young adult cancer patients exposed to doxorubicin: an opinion article
by: Christina Carfagnini, et al.
Published: (2024-11-01) -
Oral delivery of the non-β-blocking R-carvedilol enantiomer for skin cancer chemoprevention in SKH-1 mice
by: Pabitra K. Sardar, et al.
Published: (2025-01-01)